QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 deal-dispatch-abbott-tpg-and-lonza-make-major-moves-mm-custard-and-new-fortress-energy-struggle

Abbott buys Exact Sciences for $21B; TPG invests $1B in Tata Consultancy; and New Fortress Energy is on bankruptcy watch.

 abbotts-21-billion-exact-sciences-buyout-reshapes-cancer-diagnostics

Abbott will acquire Exact Sciences for $21 billion, adding Cologuard and expanding its diagnostics portfolio as analysts highli...

Core News & Articles

Abbott (NYSE:ABT) and Exact Sciences (NASDAQ:EXAS) today announced a definitive agreement for Abbott to acquire Exact Sciences,...

 btig-reiterates-buy-on-abbott-laboratories-maintains-145-price-target

BTIG analyst Marie Thibault reiterates Abbott Laboratories (NYSE:ABT) with a Buy and maintains $145 price target.

Core News & Articles

https://www.bloomberg.com/news/articles/2025-11-19/abbott-weighs-takeover-of-cancer-test-maker-exact-sciences

Core News & Articles

- Reuters

 barclays-maintains-overweight-on-abbott-laboratories-raises-price-target-to-162

Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $15...

 analyst-sees-noise-in-q3-pl-affirms-abbotts-medtech-strength

Abbott eyes 10% EPS growth in 2026 with CGM momentum, new nutrition contracts, and medical device launches driving global expan...

 raymond-james-maintains-outperform-on-abbott-laboratories-raises-price-target-to-146

Raymond James analyst Jayson Bedford maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target ...

 evercore-isi-group-maintains-outperform-on-abbott-laboratories-lowers-price-target-to-142

Evercore ISI Group analyst Vijay Kumar maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price targe...

 rbc-capital-reiterates-outperform-on-abbott-laboratories-maintains-147-price-target

RBC Capital analyst Shagun Singh reiterates Abbott Laboratories (NYSE:ABT) with a Outperform and maintains $147 price target.

 wells-fargo-maintains-overweight-on-abbott-laboratories-raises-price-target-to-146

Wells Fargo analyst Lawrence Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price targe...

 bank-earnings-lift-wall-street-gold-hits-4200-whats-moving-markets-wednesday

Wall Street rose on Wednesday, with investor optimism lifted by strong bank and corporate earnings alongside growing expectatio...

 abbott-tightens-annual-sales-forecast-as-q3-sales-miss-expectations

Abbott stock fell as Q3 sales missed estimates and 2025 earnings guidance was narrowed despite solid growth in medical devices.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION